59 related articles for article (PubMed ID: 38517215)
21. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
[TBL] [Abstract][Full Text] [Related]
22. Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
Chaudhary A; Madhavan R; Babji S; Raju R; Syed C; Kumar A; Saravanan P; Sharon Nikitha O; Leander Xavier JV; David Chelladurai JS; Deborah AA; George A; Kang G; Rose W
Vaccine; 2023 Jul; 41(33):4808-4822. PubMed ID: 37357073
[TBL] [Abstract][Full Text] [Related]
23. Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China.
Wang X; Jiang S; Jiang S; Li X; Ai J; Lin K; Lv S; Zhang S; Li M; Li J; Dai L; Hu Z; Zhang W; Zhang Y; Wang P
Cell Discov; 2023 Jun; 9(1):64. PubMed ID: 37369648
[No Abstract] [Full Text] [Related]
24. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.
Hosseinian S; de Assis R; Khalil G; Luu MK; Jain A; Horvath P; Nakajima R; Palma AM; Hoang A; Razzak E; Garcia N; Alger J; Kalantari M; Silzel EK; Jasinskas A; Zaldivar F; Schubl SD; Felgner PL; Khan S
Front Immunol; 2023; 14():1166261. PubMed ID: 37266444
[TBL] [Abstract][Full Text] [Related]
25. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
[TBL] [Abstract][Full Text] [Related]
26. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
27. Hybrid Immunity More Protective Than Prior SARS-CoV-2 Infection Alone.
Larkin H
JAMA; 2023 Feb; 329(7):531. PubMed ID: 36723971
[No Abstract] [Full Text] [Related]
28. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
Bobrovitz N; Ware H; Ma X; Li Z; Hosseini R; Cao C; Selemon A; Whelan M; Premji Z; Issa H; Cheng B; Abu Raddad LJ; Buckeridge DL; Van Kerkhove MD; Piechotta V; Higdon MM; Wilder-Smith A; Bergeri I; Feikin DR; Arora RK; Patel MK; Subissi L
Lancet Infect Dis; 2023 May; 23(5):556-567. PubMed ID: 36681084
[TBL] [Abstract][Full Text] [Related]
29. Covid-19: What do we know about XBB.1.5 and should we be worried?
Mahase E
BMJ; 2023 Jan; 380():153. PubMed ID: 36657748
[No Abstract] [Full Text] [Related]
30. Demographic comparison of the first, second and third waves of COVID-19 in a tertiary care hospital at Jaipur, India.
Singh S; Sharma A; Gupta A; Joshi M; Aggarwal A; Soni N; Sana ; Jain DK; Verma P; Khandelwal D; Singh V
Lung India; 2022; 39(6):525-531. PubMed ID: 36629231
[TBL] [Abstract][Full Text] [Related]
31. Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection.
Jiang XL; Zhu KL; Wang XJ; Wang GL; Li YK; He XJ; Sun WK; Huang PX; Zhang JZ; Gao HX; Dai EH; Ma MJ
Lancet Infect Dis; 2023 Jan; 23(1):28-30. PubMed ID: 36543471
[No Abstract] [Full Text] [Related]
32. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
[TBL] [Abstract][Full Text] [Related]
33. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant.
Qu P; Evans JP; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2022 Nov; 30(11):1518-1526.e4. PubMed ID: 36240764
[TBL] [Abstract][Full Text] [Related]
34. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
[TBL] [Abstract][Full Text] [Related]
35. Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study.
Parai D; Choudhary HR; Dash GC; Behera S; Mishra N; Pattnaik D; Raghav SK; Mishra SK; Sahoo SK; Swain A; Mohapatra I; Pattnaik M; Moharana A; Jena SR; Praharaj I; Subhadra S; Kanungo S; Bhattacharya D; Pati S
Front Microbiol; 2022; 13():942659. PubMed ID: 36016787
[TBL] [Abstract][Full Text] [Related]
36. Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern.
Kumar NP; Banurekha VV; Kumar CPG; Nancy A; Padmapriyadarsini C; Shankar S; Hanna LE; Murhekar M; Devi KRU; Babu S
J Travel Med; 2022 Sep; 29(6):. PubMed ID: 35900009
[TBL] [Abstract][Full Text] [Related]
37. Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
Vadrevu KM; Ganneru B; Reddy S; Jogdand H; Raju D; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai SK; Ella R; Abraham P; Prasad S; Ella K
Sci Rep; 2022 Jul; 12(1):12038. PubMed ID: 35835822
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural Severe Acute Respiratory Syndrome Coronavirus 2 Infection (With or Without Subsequent Coronavirus Disease 2019 [COVID-19] Vaccination) Versus 2-Dose COVID-19 Vaccination.
Lim SY; Park S; Kim JY; Kim S; Jee Y; Kim SH
Clin Infect Dis; 2022 Dec; 75(12):2243-2246. PubMed ID: 35686300
[TBL] [Abstract][Full Text] [Related]
39. A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days.
Liang XM; Xu QY; Jia ZJ; Wu MJ; Liu YY; Lin LR; Liu LL; Yang TC
Front Immunol; 2022; 13():876037. PubMed ID: 35572536
[TBL] [Abstract][Full Text] [Related]
40. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.
Belik M; Jalkanen P; Lundberg R; Reinholm A; Laine L; Väisänen E; Skön M; Tähtinen PA; Ivaska L; Pakkanen SH; Häkkinen HK; Ortamo E; Pasternack A; Ritvos MA; Naves RA; Miettinen S; Sironen T; Vapalahti O; Ritvos O; Österlund P; Kantele A; Lempainen J; Kakkola L; Kolehmainen P; Julkunen I
Nat Commun; 2022 May; 13(1):2476. PubMed ID: 35513437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
